Renee Gaeta, serving as the Chief Financial Officer for Outset Medical, Inc. (NASDAQ: OM), recently executed a stock transaction on June 3, 2026. The transaction involved the sale of 17,672 shares of the company's common stock, resulting in a total value of $87,299. These shares were sold at a price of $4.94 per share. The stock currently trades at $4.58, reflecting a 77% decline over the past year. Despite this decline, analysis suggests the company appears undervalued based on its Fair Value assessment, placing it among stocks on the Most Undervalued list.
The transaction was identified as a "sell to cover" sale, executed to satisfy tax withholding obligations. This sale was in connection with the vesting of 32,856 shares of common stock underlying restricted stock units (RSUs) granted to Ms. Gaeta on June 10, 2025. The filing noted that this transaction does not represent a discretionary trade by the reporting person. Following this transaction, Ms. Gaeta directly holds 113,753 shares of Outset Medical common stock.
In other recent news, Outset Medical reported its Q1 2026 earnings, revealing a 6% decline in revenue to $27.9 million compared to the same quarter last year. Despite the decrease in revenue, the company maintained its full-year revenue guidance, projecting figures between $125 million and $130 million. This strategic focus on innovation and cybersecurity seems to have positively influenced market perceptions. Analysts and investors appear optimistic about the company’s direction, as evidenced by the market’s favorable response. These developments highlight Outset Medical’s commitment to advancing its strategic initiatives. The company’s emphasis on innovation may be a key factor in its future performance. Investors are closely watching how these strategies will unfold in the coming quarters.